Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Mar;61(3):420–424. doi: 10.1038/bjc.1990.92

The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model.

R G Melton 1, F Searle 1, R F Sherwood 1, K D Bagshawe 1, J A Boden 1
PMCID: PMC1971295  PMID: 2328209

Abstract

The in vivo localising and clearance properties of conjugates of the folate-degrading enzyme carboxypeptidase G2 (CPG2) with anti-human chorionic gonadotrophin (W14A) were measured in nude mice bearing CC3 choriocarcinoma xenografts. Conjugates of W14A-F (ab')2 fragment coupled to CPG2 localised in tumour as effectively as native antibody alone but showed lower uptake in other major tissues. The clearance rates of conjugates prepared with intact antibody or F (ab')2 fragment were shown to be up to five-fold faster than for native antibody and two-fold compared to F (ab')2 fragment. Molecular weight analysis of residual conjugate in the blood showed that no degradation of conjugate to its component molecules occurred during circulation. It was concluded that F (ab')2: CPG2 conjugates offered the greatest potential for targeting applications.

Full text

PDF
420

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagshawe K. D. Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer. 1987 Nov;56(5):531–532. doi: 10.1038/bjc.1987.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bagshawe K. D. Marker proteins as indicators of tumour response to therapy. Br J Cancer Suppl. 1980 Apr;4:186–190. [PMC free article] [PubMed] [Google Scholar]
  3. Bagshawe K. D. Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers--where do we go from here? Br J Cancer. 1983 Aug;48(2):167–175. doi: 10.1038/bjc.1983.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Begent R. H. Recent advances in tumour imaging. Use of radiolabelled antitumour antibodies. Biochim Biophys Acta. 1985;780(2):151–166. doi: 10.1016/0304-419x(84)90003-9. [DOI] [PubMed] [Google Scholar]
  5. Bertino J. R., Levitt M., McCullough J. L., Chabner B. New approaches to chemotherapy with folate antagonists: use of leucovorin "rescue" and enzymic folate depletion. Ann N Y Acad Sci. 1971 Nov 30;186:486–495. [PubMed] [Google Scholar]
  6. HUNTER W. M., GREENWOOD F. C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962 May 5;194:495–496. doi: 10.1038/194495a0. [DOI] [PubMed] [Google Scholar]
  7. Hagan P. L., Halpern S. E., Dillman R. O., Shawler D. L., Johnson D. E., Chen A., Krishnan L., Frincke J., Bartholomew R. M., David G. S. Tumor size: effect on monoclonal antibody uptake in tumor models. J Nucl Med. 1986 Mar;27(3):422–427. [PubMed] [Google Scholar]
  8. Kalghatgi K. K., Moroson B. A., Horváth C., Bertino J. R. Enhancement of antitumor activity of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (triazinate) with carboxypeptidase G1. Cancer Res. 1979 Sep;39(9):3441–3445. [PubMed] [Google Scholar]
  9. Melton R. G., Wiblin C. N., Baskerville A., Foster R. L., Sherwood R. F. Covalent linkage of carboxypeptidase G2 to soluble dextrans--II. In vivo distribution and fate of conjugates. Biochem Pharmacol. 1987 Jan 1;36(1):113–121. doi: 10.1016/0006-2952(87)90388-1. [DOI] [PubMed] [Google Scholar]
  10. Melton R. G., Wiblin C. N., Foster R. L., Sherwood R. F. Covalent linkage of carboxypeptidase G2 to soluble dextrans--I. Properties of conjugates and effects on plasma persistence in mice. Biochem Pharmacol. 1987 Jan 1;36(1):105–112. doi: 10.1016/0006-2952(87)90387-x. [DOI] [PubMed] [Google Scholar]
  11. Minton N. P., Atkinson T., Bruton C. J., Sherwood R. F. The complete nucleotide sequence of the Pseudomonas gene coding for carboxypeptidase G2. Gene. 1984 Nov;31(1-3):31–38. doi: 10.1016/0378-1119(84)90192-6. [DOI] [PubMed] [Google Scholar]
  12. PRESSMAN D., KORNGOLD L. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer. 1953 May;6(3):619–623. doi: 10.1002/1097-0142(195305)6:3<619::aid-cncr2820060319>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  13. Rostock R. A., Kopher K. A., Bauer T. W., Klein J. L. Factors that affect antiferritin localization in four rat hepatoma models. Cancer Drug Deliv. 1985 Spring;2(2):139–145. doi: 10.1089/cdd.1985.2.139. [DOI] [PubMed] [Google Scholar]
  14. Searle F., Adam T., Boden J. A. Distribution of intact and Fab2(1) fragments of anti-human chorionic gonadotrophin antibodies in nude mice bearing human choriocarcinoma xenografts. Cancer Immunol Immunother. 1986;21(3):205–208. doi: 10.1007/BF00199363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Searle F., Bier C., Buckley R. G., Newman S., Pedley R. B., Bagshawe K. D., Melton R. G., Alwan S. M., Sherwood R. F. The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitro. Br J Cancer. 1986 Mar;53(3):377–384. doi: 10.1038/bjc.1986.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Searle F., Boden J., Lewis J. C., Bagshawe K. D. A human choriocarcinoma xenograft in nude mice; a model for the study of antibody localization. Br J Cancer. 1981 Aug;44(2):137–144. doi: 10.1038/bjc.1981.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Searle F., Partridge C. S., Kardana A., Green A. J., Buckley R. G., Begent R. H., Rawlins G. A. Preparation and properties of mouse monoclonal antibody (W14A) to human chorionic gonadotropin. Int J Cancer. 1984 Apr 15;33(4):429–434. doi: 10.1002/ijc.2910330402. [DOI] [PubMed] [Google Scholar]
  18. Sherwood R. F., Melton R. G., Alwan S. M., Hughes P. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur J Biochem. 1985 May 2;148(3):447–453. doi: 10.1111/j.1432-1033.1985.tb08860.x. [DOI] [PubMed] [Google Scholar]
  19. Worrell N. R., Cumber A. J., Parnell G. D., Ross W. C., Forrester J. A. Fate of an antibody-ricin A chain conjugate administered to normal rats. Biochem Pharmacol. 1986 Feb 1;35(3):417–423. doi: 10.1016/0006-2952(86)90214-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES